Skip to main content
Top

02-11-2017 | Breast cancer | Article

Safety of fertility preservation in breast cancer patients in a register-based matched cohort study

Journal: Breast Cancer Research and Treatment

Authors: Kenny A. Rodriguez-Wallberg, Sandra Eloranta, Kamilla Krawiec, Agneta Lissmats, Jonas Bergh, Annelie Liljegren

Publisher: Springer US

Abstract

Purpose

To determine if women with breast cancer that undergo fertility preservation (FP), with or without hormonal stimulation, present with an increased risk of breast cancer recurrence.

Methods

A matched cohort study on women with breast cancer attempting to ensure FP in Stockholm from 1999 to 2013 [exposed women (n = 188), age-matched unexposed controls (n = 378)] was designed using the Stockholm regional data from the Swedish National Breast Cancer Quality Register. Breast cancer relapse rates [incidence rate ratio (IRR)] and 95% confidence interval (CI) were estimated using Cox regression and adjusted for potential confounding factors. Completeness of the registry at the time of the study was close to 99%.

Results

Most women attempted FP by hormonal stimulation treatment (n = 148, 79%) with the objective of freezing their eggs or embryos. A smaller group elected FP methods without hormone stimulation (n = 40, 21%). Women who received hormone stimulation did not present with a higher relapse rate than unexposed control women in a model adjusted for age and calendar period of diagnosis (IRR 0.59, 95% CI 0.34–1.04). The results remained virtually unchanged after adjustment for tumor size, estrogen receptor status, affected lymph nodes, and chemotherapy treatment (IRR 0.66, 95% CI 0.37–1.17).

Conclusion

Evidence was not found that fertility preservation, with or without hormonal stimulation, was associated with an increased risk of breast cancer recurrence. The high coverage rate of this population-based study supports the safe practice of fertility preservation in young women with breast cancer.
Literature
1.
Fredholm H, Eaker S, Frisell J, Holmberg L, Fredriksson I, Lindman H (2009) Breast cancer in young women: poor survival despite intensive treatment. PLoS ONE 4:e7695CrossRefPubMedPubMedCentral
2.
Rodriguez-Wallberg KA (2012) Principles of cancer treatment: impact on reproduction. Adv Exp Med Biol 732:1–8CrossRefPubMed
3.
Lee SJ, Schover LR, Partridge AH et al (2006) American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 24:2917–2931CrossRefPubMed
4.
Loren AW, Mangu PB, Beck LN et al (2013) Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 31:2500–2510CrossRefPubMedPubMedCentral
5.
Partridge AH, Ruddy KJ, Kennedy J, Winer EP (2012) Model program to improve care for a unique cancer population: young women with breast cancer. J Oncol Pract 8:e105–e110CrossRefPubMedPubMedCentral
6.
Doyle JO, Richter KS, Lim J, Stillman RJ, Graham JR, Tucker MJ (2016) Successful elective and medically indicated oocyte vitrification and warming for autologous in vitro fertilization, with predicted birth probabilities for fertility preservation according to number of cryopreserved oocytes and age at retrieval. Fertil Steril 105(459–66):e2
7.
Mitwally MF, Bhakoo HS, Crickard K, Sullivan MW, Batt RE, Yeh J (2006) Estradiol production during controlled ovarian hyperstimulation correlates with treatment outcome in women undergoing in vitro fertilization-embryo transfer. Fertil Steril 86:588–596CrossRefPubMed
8.
Rodriguez-Wallberg KA, Oktay K (2012) Fertility preservation and pregnancy in women with and without BRCA mutation-positive breast cancer. Oncologist 17:1409–1417CrossRefPubMedPubMedCentral
9.
Chian RC, Uzelac PS, Nargund G (2013) In vitro maturation of human immature oocytes for fertility preservation. Fertil Steril 99:1173–1181CrossRefPubMed
10.
Oktay K, Buyuk E, Davis O, Yermakova I, Veeck L, Rosenwaks Z (2003) Fertility preservation in breast cancer patients: IVF and embryo cryopreservation after ovarian stimulation with tamoxifen. Hum Reprod 18:90–95CrossRefPubMed
11.
Oktay K, Buyuk E, Libertella N, Akar M, Rosenwaks Z (2005) Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. J Clin Oncol 23:4347–4353CrossRefPubMed
12.
Noyes N, Labella PA, Grifo J, Knopman JM (2010) Oocyte cryopreservation: a feasible fertility preservation option for reproductive age cancer survivors. J Assist Reprod Genet 27:495–499CrossRefPubMedPubMedCentral
13.
Oktay K, Turan V, Bedoschi G, Pacheco FS, Moy F (2015) Fertility preservation success subsequent to concurrent aromatase inhibitor treatment and ovarian stimulation in women with breast cancer. J Clin Oncol 33:2424–2429CrossRefPubMedPubMedCentral
14.
Azim AA, Costantini-Ferrando M, Oktay K (2008) Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study. J Clin Oncol 26:2630–2635CrossRefPubMed
15.
Kim J, Turan V, Oktay K (2016) Long-term safety of letrozone and gonadotropin stimulation for fertility preservation in women with breast cancer. J Clin Endocrinol Metab jc20153878
16.
Oktay K, Turkcuoglu I, Rodriguez-Wallberg KA (2010) GnRH agonist trigger for women with breast cancer undergoing fertility preservation by aromatase inhibitor/FSH stimulation. Reprod Biomed Online 20:783–788CrossRefPubMedPubMedCentral
17.
Rodriguez-Wallberg KA, Tanbo T, Tinkanen HI et al (2016) Ovarian tissue cryopreservation and transplantation among alternatives for fertility preservation in the Nordic countries – compilation of 20 years of academic multicentre experience. Acta Obstet Gynecol Scand. https://​doi.​org/​10.​1111/​aogs.​12934. www.​cancercentrum.​se
18.
Partridge AH (2008) Fertility preservation: a vital survivorship issue for young women with breast cancer. J Clin Oncol 26:2612–2613CrossRefPubMed
19.
Rosen A, Rodriguez-Wallberg KA, Rosenzweig L (2009) Psychosocial distress in young cancer survivors. Semin Oncol Nurs 25:268–277CrossRefPubMed
20.
Schover LR (2005) Motivation for parenthood after cancer: a review. J Natl Cancer Inst Monogr 2005:2–5CrossRef
21.
Benedict C, Shuk E, Ford JS (2016) Fertility issues in adolescent and young adult cancer survivors. J Adolesc Young Adult Oncol 5:48–57CrossRefPubMedPubMedCentral
22.
Grambsch PM, Therneau TM (1994) Proportional hazards test and diagnostics based on weighted residuals. Biometrika 81:515–526CrossRef
23.
Lambert PC, Royston P (2009) Further development of flexible parametric models for survival analysis. Stata J 9:265–290
24.
Rodriguez-Wallberg KA, Oktay K (2012) Recent advances in oocyte and ovarian tissue cryopreservation and transplantation. Best Pract Res Clin Obstet Gynaecol 26:391–405CrossRefPubMedPubMedCentral
25.
Council of Drugs (1960) Androgens and estrogens in the treatment of disseminated mammary carcinoma: retrospective study of nine hundred forty-four patients. JAMA 172:1271–1283CrossRef
26.
Kennedy BJ (1965) Diethylstilbestrol versus testosterone propionate therapy in advanced breast cancer. Surg Gynecol Obstet 120:1246–1250PubMed
27.
Ingle JN, Ahmann DL, Green SJ, Edmonson JH, Bisel HF, Kvols LK, Nichols WC, Creagan ET, Hahn RG, Rubin J, Frytak S (1981) Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N Eng J Med 304:16–21CrossRef
28.
Quinn GP, Vadaparampil ST, Bell-Ellison BA, Gwede CK, Albrecht TL (2008) Patient-physician communication barriers regarding fertility preservation among newly diagnosed cancer patients. Soc Sci Med 66:784–789CrossRefPubMed
29.
Balthazar U, Deal AM, Fritz MA, Kondapalli LA, Kim JY, Mersereau JE (2012) The current fertility preservation consultation model: are we adequately informing cancer patients of their options? Hum Reprod 27:2413–2419CrossRefPubMed
30.
Quinn GP, Woodruff TK, Knapp CA, Bowman ML, Reinecke J, Vadaparampil ST (2016) Expanding the oncofertility workforce: training allied health professionals to improve health outcomes for adolescents and young adults. J Adolesc Young Adult Oncol